
Dattatraya Patil

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6339953/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy NaÃ⁻ve Men. Journal of Urology, 2015, 194, 65-72.	0.4	137
2	Association Between Combined <i>TMPRSS2:ERG</i> and <i>PCA3</i> RNA Urinary Testing and Detection of Aggressive Prostate Cancer. JAMA Oncology, 2017, 3, 1085.	7.1	120
3	Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium. European Urology, 2019, 75, 523-531.	1.9	58
4	The Movember Foundation's GAP3 cohort: a profile of the largest global prostate cancer active surveillance database to date. BJU International, 2018, 121, 737-744.	2.5	51
5	Patient Frailty and Discharge Disposition Following Radical Cystectomy. Clinical Genitourinary Cancer, 2017, 15, e615-e621.	1.9	50
6	Circulating microRNAs in plasma as potential biomarkers for the early detection of prostate cancer. Prostate, 2018, 78, 411-418.	2.3	47
7	Onodera's Prognostic Nutritional Index as an Independent Prognostic Factor in Clear Cell Renal Cell Carcinoma. Urology, 2016, 96, 99-105.	1.0	43
8	Adoption of Prebiopsy Magnetic Resonance Imaging for Men Undergoing Prostate Biopsy in the United States. Urology, 2018, 117, 57-63.	1.0	43
9	Prospective evaluation of fluciclovine (18 F) PET-CT and MRI in detection of recurrent prostate cancer in non-prostatectomy patients. European Journal of Radiology, 2018, 102, 1-8.	2.6	32
10	A fourâ€group urine risk classifier for predicting outcomes in patients with prostate cancer. BJU International, 2019, 124, 609-620.	2.5	30
11	Detection of prostate cancerâ€specific transcripts in extracellular vesicles isolated from postâ€DRE urine. Prostate, 2017, 77, 990-999.	2.3	29
12	epiCaPture: A Urine DNA Methylation Test for Early Detection of Aggressive Prostate Cancer. JCO Precision Oncology, 2019, 2019, 1-18.	3.0	27
13	Circulating microRNAs in plasma among men with lowâ€grade and highâ€grade prostate cancer at prostate biopsy. Prostate, 2019, 79, 961-968.	2.3	26
14	Sarcopenia and modified Glasgow Prognostic Score predict postsurgical outcomes in localized renal cell carcinoma. Cancer, 2021, 127, 1974-1983.	4.1	26
15	Elevated preoperative neutrophil-to-lymphocyte ratio may be associated with decreased overall survival in patients with metastatic clear cell renal cell carcinoma undergoing cytoreductive nephrectomy. Asian Journal of Urology, 2016, 3, 20-25.	1.2	24
16	Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance Initiative. European Urology Oncology, 2020, 3, 80-91.	5.4	24
17	Evaluation of programmed cell death protein 1 (PD-1) expression as a prognostic biomarker in patients with clear cell renal cell carcinoma. Oncolmmunology, 2018, 7, e1413519.	4.6	21
18	Relief of Urinary Symptom Burden after Primary Prostate Cancer Treatment. Journal of Urology, 2017, 197, 376-384.	0.4	18

#	Article	lF	CITATIONS
19	Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts. European Urology, 2019, 76, 693-702.	1.9	18
20	Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator. European Urology Focus, 2019, 5, 54-61.	3.1	18
21	Urologist Use of Cystoscopy for Patients Presenting With Hematuria in the United States. Urology, 2017, 100, 20-26.	1.0	17
22	[¹⁸ F]Fluciclovine Positron Emission Tomography/Computerized Tomography for Preoperative Staging in Patients with Intermediate to High Risk Primary Prostate Cancer. Journal of Urology, 2020, 204, 734-740.	0.4	16
23	Safety and Efficacy of Ureteral Stent Placement at the Bedside Using Local Anesthesia. Journal of Urology, 2016, 195, 1886-1890.	0.4	15
24	Treatment of men with high-risk prostate cancer based on race, insurance coverage, and access to advanced technology. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 250-256.	1.6	15
25	Personalised biopsy schedules based on risk of Gleason upgrading for patients with lowâ€risk prostate cancer on active surveillance. BJU International, 2021, 127, 96-107.	2.5	15
26	A novel preoperative inflammatory marker prognostic score in patients with localized and metastatic renal cell carcinoma. Asian Journal of Urology, 2017, 4, 230-238.	1.2	13
27	Female Gender Predicts Favorable Prognosis in Patients With Non-metastatic Clear Cell Renal Cell Carcinoma Undergoing Curative Surgery: Results From the International Marker Consortium for Renal Cancer (INMARC). Clinical Genitourinary Cancer, 2020, 18, 111-116.e1.	1.9	13
28	A panel of selected serum protein biomarkers for the detection of aggressive prostate cancer. Theranostics, 2021, 11, 6214-6224.	10.0	13
29	Preoperative Elevation of C-Reactive Protein Is a Predictor for Adverse Oncologic Survival Outcomes for Renal Cell Carcinoma: Analysis from the International Marker Consortium Renal Cancer (INMARC). Clinical Genitourinary Cancer, 2021, 19, e206-e215.	1.9	13
30	Predicting childhood chronic kidney disease severity in infants with posterior urethral valve: a critical analysis of creatinine values in the first year of life. Pediatric Nephrology, 2022, 37, 1339-1345.	1.7	13
31	Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. European Urology Open Science, 2022, 35, 59-67.	0.4	13
32	Risk of Readmission After Uncomplicated Hospitalization After Radical Cystectomy. Clinical Genitourinary Cancer, 2018, 16, e705-e710.	1.9	11
33	Expanded Prostate Cancer Index Composite-26 (EPIC-26) Online: Validation of an Internet-Based Instrument for Assessment of Health-Related Quality of Life After Treatment for Localized Prostate Cancer. Urology, 2019, 127, 53-60.	1.0	11
34	Quantification of body composition in renal cell carcinoma patients: Comparing computed tomography and magnetic resonance imaging measurements. European Journal of Radiology, 2020, 132, 109307.	2.6	11
35	Elevated preoperative Câ€reactive protein is associated with renal functional decline and nonâ€cancer mortality in surgically treated renal cell carcinoma: analysis from the INternational Marker Consortium for Renal Cancer (INMARC). BJU International, 2021, 127, 311-317.	2.5	11
36	Role of a Preoperative Catheter Regimen in Achieving Early Primary Endoscopic Valve Ablation in Neonates with Posterior Urethral Valves. Journal of Urology, 2021, 205, 1792-1797.	0.4	10

#	Article	IF	CITATIONS
37	Genetic factors associated with prostate cancer conversion from active surveillance to treatment. Human Genetics and Genomics Advances, 2022, 3, 100070.	1.7	10
38	Surgical sterilization among US men and women with employer-based insurance: A claims data analysis. Contraception, 2018, 98, 247-251.	1.5	9
39	Erectile Dysfunction and Sexual Problems Two to Three Years After Prostatectomy Among American, Norwegian, and Spanish Patients. Clinical Genitourinary Cancer, 2016, 14, e265-e273.	1.9	8
40	Consistent Biopsy Quality and Gleason Grading Within the Global Active Surveillance Global Action Plan 3 Initiative: A Prerequisite for Future Studies. European Urology Oncology, 2019, 2, 333-336.	5.4	8
41	Outcomes in Patients with Renal Cell Carcinoma Undergoing Inferior Vena Cava Ligation without Reconstruction versus Thrombectomy: A Retrospective, Case Controlled Study. Journal of Urology, 2021, 205, 383-391.	0.4	8
42	A prospective study of patient reported urinary incontinence among American, Norwegian and Spanish men 1 year after prostatectomy. Asian Journal of Urology, 2020, 7, 161-169.	1.2	7
43	Prospective Multicenter Comparison of Open and Robotic Radical Prostatectomy: The PROST-QA/RP2 Consortium. Journal of Urology, 2022, 207, 127-136.	0.4	7
44	Evaluation of a 24â€gene signature for prognosis of metastatic events and prostate cancerâ€specific mortality. BJU International, 2017, 119, 961-967.	2.5	6
45	Impact of prebiopsy magnetic resonance imaging of the prostate on cancer detection and treatment patterns. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 181.e15-181.e21.	1.6	6
46	Disparities in magnetic resonance imaging of the prostate for traditionally underserved patients with prostate cancer. Cancer, 2021, 127, 2974-2979.	4.1	6
47	Sarcopenia and systemic inflammation are associated with decreased survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. Cancer, 2022, 128, 2073-2084.	4.1	6
48	Contemporary Patterns of Third-line Treatments for Privately Insured Individuals With Overactive Bladder in the United States. Urology, 2020, 142, 87-93.	1.0	5
49	Disparities in Cancer Specific and Overall Survival Outcomes in African Americans With Renal Cell Carcinoma: Analysis From the International Marker Consortium for Renal Cancer (INMARC). Urology, 2022, 163, 164-176.	1.0	5
50	Physical Activity Profiles of Overweight and Obese Women in Rural Georgia. JAMA Internal Medicine, 2014, 174, 148.	5.1	4
51	What are Infertility Treatment Center Websites Telling Couples about MaleÂFactor Infertility?. Urology Practice, 2016, 3, 449-455.	0.5	4
52	Major histocompatibility complex I upregulation in clear cell renal cell carcinoma is associated with increased survival. Asian Journal of Urology, 2016, 3, 75-81.	1.2	4
53	Renal cell carcinoma with vena caval involvement: a contemporary clinicopathologic analysis of 53 cases. Human Pathology, 2016, 49, 83-89.	2.0	4
54	MP16-03 UTILITY OF INFLAMMATORY MARKERS IN PROGNOSIS FOR PATIENTS WITH RENAL CELL CARCINOMA AND VENA CAVA TUMOR THROMBUS. Journal of Urology, 2017, 197, .	0.4	4

#	Article	IF	CITATIONS
55	Use of Office Versus Ambulatory Surgery Center Setting and Associated Ancillary Services on Healthcare Cost Burden for Vasectomy Procedures. Urology, 2019, 129, 29-34.	1.0	4
56	Elevated Serum Cytokines and Trichomonas vaginalis Serology at Diagnosis Are Not Associated With Higher Gleason Grade or Lethal Prostate Cancer. Clinical Genitourinary Cancer, 2019, 17, 32-37.	1.9	4
57	Survival benefit with extended lymphadenectomy for advanced renal malignancy: A population-based analysis. Asian Journal of Urology, 2020, 7, 29-36.	1.2	4
58	Payments and Patient Cost Sharing for Prostate Biopsies According to Image Guidance, Practice Site and Use of Anesthesia. Urology Practice, 2020, 7, 138-144.	0.5	4
59	Dynamic Evaluation of the Modified Glasgow Prognostic Scale in Patients With Resected, Localized Clear Cell Renal Cell Carcinoma. Urology, 2020, 141, 101-107.	1.0	4
60	Longitudinal impact of bladder cancer diagnosis on common psychiatric disorders. Cancer Medicine, 2021, 10, 8412-8420.	2.8	4
61	Posterior urethral morphology on initial voiding cystourethrogram correlates to early renal outcomes in infants with posterior urethral valves. Journal of Pediatric Urology, 2022, 18, 813-819.	1.1	4
62	The Clinical Course of Patients With Prostate-Specific Antigen ≥100 ng/ml: Insight Into a Potential Population for Targeted Prostate-Specific Antigen Screening. Urology, 2018, 117, 101-107.	1.0	3
63	Hypogonadism is independently associated with varicocele repair in a contemporary cohort of men in the USA. Asian Journal of Andrology, 2019, 21, 45.	1.6	3
64	Palliative care use among bladder cancer patients treated with radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 788.e1-788.e6.	1.6	3
65	Access to Care for Infertile Men: Referral Patterns of Fertility Clinics in the United States. Urology, 2022, , .	1.0	3
66	Safety and efficacy of ureteral stent placement at the bedside under local anesthesia. Journal of the American College of Surgeons, 2014, 219, e196.	0.5	2
67	High Expression of Major Histocompatibility Complex Class I in Clear Cell Renal Cell Carcinoma Is Associated with Improved Prognosis. Urologia Internationalis, 2015, 95, 72-78.	1.3	2
68	Avoiding the Need for Bowel Anastomosis during Pelvic Exenteration—Urinary Sigmoid or Descending Colon Conduit—Short and Long Term Complications. Urology, 2019, 129, 228-233.	1.0	2
69	PD-1 expression and its impact on survival in localized clear cell renal cell carcinoma Journal of Clinical Oncology, 2016, 34, 568-568.	1.6	2
70	Defining individual recurrence risk following surgery for high risk non-metastatic renal cell carcinoma Journal of Clinical Oncology, 2018, 36, 664-664.	1.6	2
71	Magnetic resonance imaging vs. computed tomography image concordance for linear measurements and the quantification of abdominal skeletal muscle. JCSM Clinical Reports, 2022, 7, 24-29.	1.3	2
72	Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium database. Prostate, 2022, 82, 876-879.	2.3	2

#	Article	lF	CITATIONS
73	Cost of Intralesional Collagenase Clostridium Histiolyticum Therapy Versus Surgery for the Management of Peyronie's Disease: A Claims-Based Analysis (2009–2019). Sexual Medicine, 2022, 10, 1-1.	1.6	2
74	Muscle mass change using linear measurement analysis after nephrectomy for pT3 and pT4 renal cell carcinoma is associated with mortality. JCSM Rapid Communications, 2022, 5, 205-211.	1.6	2
75	MP78-18 THE RELATIONSHIP BETWEEN PREOPERATIVE C - REACTIVE PROTEIN AND FUHRMAN NUCLEAR GRADE IN STAGE T1 RENAL CELL CARCINOMA. Journal of Urology, 2016, 195, .	0.4	1
76	PD18-08 PROSPECTIVE MULTICENTER COMPARISON OF OPEN AND ROBOTIC RADICAL PROSTATECTOMY: THE PROST-QA/RP2 CONSORTIUM. Journal of Urology, 2017, 197, .	0.4	1
77	Relationship Between Preoperative C-Reactive Protein and Fuhrman Nuclear Grade in Stage T1 Renal Cell Carcinoma: A Short-Term Update. Journal of the American College of Surgeons, 2017, 225, S209.	0.5	1
78	Patterns of Initial Metastatic Recurrence After Surgery for High-Risk Nonmetastatic Renal Cell Carcinoma. Urology, 2020, 146, 152-157.	1.0	1
79	Overlapping Urological Surgeries at a Tertiary Academic Center. Urology, 2021, 148, 118-125.	1.0	1
80	Enhanced antibiotic prophylaxis and infection-related complications following prostate biopsy. World Journal of Urology, 2021, 39, 3415-3422.	2.2	1
81	Genitourinary Prosthetic Use among Prostate Cancer Survivors Treated with Radical Prostatectomy. Urology Practice, 2019, 6, 123-128.	0.5	1
82	Association of elevated C-reactive protein with oncologic outcomes in renal CELL carcinoma: A multicenter analysis Journal of Clinical Oncology, 2019, 37, 596-596.	1.6	1
83	Expectations for overall survival in mRCC patients who were selected for upfront cytoreductive nephrectomy in the targeted therapy era Journal of Clinical Oncology, 2020, 38, 646-646.	1.6	1
84	Association of De Ritis Ratio and Neutrophil Lymphocyte Ratio with renal functional decline and all-cause mortality in renal cell carcinoma Journal of Clinical Oncology, 2020, 38, 741-741.	1.6	1
85	Antibiotic Stewardship for Ambulatory Urological Procedures: Cystoscopy and Vasectomy. Urology Practice, 2020, 7, 272-278.	0.5	1
86	Microhematuria in women: Prevalence of malignancy and risk score evaluation. Urology, 2021, , .	1.0	1
87	Covariate adjustment in continuous biomarker assessment. Biometrics, 2023, 79, 39-48.	1.4	1
88	Transplant Radical Nephrectomy and Transplant Radical Nephroureterectomy for Renal Cancer: Postoperative and Survival Outcomes. Annals of Transplantation, 2020, 25, e925865.	0.9	1
89	Prognostic Significance of C-reactive Protein in Patients With Non-metastatic Papillary Renal Cell Carcinoma: Results from the INternational Marker Consortium for Renal Cancer (INMARC) Cohort. Clinical Genitourinary Cancer, 2022, 20, e276-e282.	1.9	1
90	PI-08 COMBINING URINE PCA3 AND TMPRSS2: ERG TESTS TO REFINE PROSTATE CANCER DETECTION – VALIDATION STUDY AND HEALTH ECONOMIC ANALYSIS. Journal of Urology, 2015, 193, .	0.4	0

#	Article	IF	CITATIONS
91	A new inflammatory-based marker prognostic score in a large cohort of patients with localized clear cell renal cell carcinoma. Journal of the American College of Surgeons, 2015, 221, e147.	0.5	0
92	PD46-02 MULTICENTER EVALUATION OF THE PROSTATE HEALTH INDEX (PHI) FOR DETECTION OF AGGRESSIVE PROSTATE CANCER IN BIOPSY-NAÃVE MEN. Journal of Urology, 2015, 193, .	0.4	0
93	PD46-05 MULTI-CENTER PROSPECTIVE STUDY OF URINE RNA TESTING AS A STRATEGY FOR PROSTATE CANCER SCREENING: COLLABORATION BETWEEN UROLOGY, PRIMARY CARE, AND COMMUNITY OUTREACH. Journal of Urology, 2015, 193, .	0.4	0
94	MP44-08 PRE-OPERATIVE MODIFIED GLASGOW PROGNOSTIC SCORE AS AN INDEPENDENT PROGNOSIS FACTOR IN A LARGE U.S. POPULATION. Journal of Urology, 2015, 193, .	0.4	0
95	MP16-17 THE VALUE OF PATHOLOGIC EXAMINATION OF THE FORESKIN FOLLOWING CIRCUMCISION. Journal of Urology, 2015, 193, .	0.4	0
96	MP4-04 CLINICAL OUTCOMES OF CONSERVATIVELY MANAGED PROSTATE CANCER AMONG AFRICAN AMERICAN MEN. Journal of Urology, 2015, 193, .	0.4	0
97	The Value of Pathological Examination of the Foreskin Following Circumcision. Urology Practice, 2015, 2, 149-153.	0.5	0
98	Patient Frailty and Discharge Disposition after Radical Cystectomy. Journal of the American College of Surgeons, 2016, 223, S161-S162.	0.5	0
99	MP37-01 EXPANDED PROSTATE CANCER INDEX COMPOSITE-26 (EPIC-26) ONLINE: VALIDATION OF AN INTERNET-BASED INSTRUMENT FOR ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE AFTER TREATMENT FOR LOCALIZED PROSTATE CANCER. Journal of Urology, 2016, 195, .	0.4	0
100	MP73-18 EXTERNAL VALIDATION OF PREOPERATIVE AST/ALT (DE-RITIS) RATIO AS A PROGNOSTIC INDICATOR IN LOCALIZED AND METASTATIC RENAL CELL CARCINOMA. Journal of Urology, 2016, 195, .	0.4	0
101	MP02-09 TARGETED SEQUENCING OF PROSTATE CANCER-ASSOCIATED RNAS IN EXTRACELLULAR VESICLES FROM POST-DRE URINE. Journal of Urology, 2016, 195, .	0.4	0
102	Author Reply. Urology, 2016, 96, 105.	1.0	0
103	MP06-12 FRAIL PATIENTS ARE LESS LIKELY TO BE DISCHARGED TO HOME AFTER CYSTECTOMY. Journal of Urology, 2016, 195, .	0.4	0
104	Trends in diagnosis and management of varicoceles among U.S. men. Fertility and Sterility, 2017, 108, e45-e46.	1.0	0
105	MP35-15 TRENDS IN DIAGNOSIS AND MANAGEMENT OF VARICOCELES AMONG U.S. MEN. Journal of Urology, 2017, 197, .	0.4	0
106	MP32-01 PROSTATE BIOPSY PAYMENTS TO AMBULATORY SURGERY CENTERS STABLE AS PHYSICIAN REIMBURSEMENT FALLS: SUMMARY OF MEDICARE REIMBURSEMENT 2012 – 2014. Journal of Urology, 2017, 197, .	0.4	0
107	MP76-01 SHARP DECREASE IN PROSTATE BIOPSY INCIDENCE WITH WIDE GEOGRAPHIC VARIATION FOLLOWING TASK FORCE PROSTATE CANCER SCREENING RECOMMENDATIONS. Journal of Urology, 2017, 197, .	0.4	0
108	MP86-04 NEW-ONSET DEPRESSION AND MENTAL HEALTH-RELATED QUALITY OF LIFE FOLLOWING PROSTATE CANCER DIAGNOSIS WITHOUT TREATMENT. Journal of Urology, 2017, 197, .	0.4	0

#	Article	IF	CITATIONS
109	PD18-03 LONG-TERM HEALTH RELATED QUALITY OF LIFE IN PROSTATE CANCER PATIENTS REQUIRING RADIOTHERAPY AFTER RADICAL PROSTATECTOMY. Journal of Urology, 2017, 197, .	0.4	0
110	MP08-09 POPULATION-LEVEL CANCER DETECTION AND PATTERNS OF CARE FOLLOWING MRI-GUIDED PROSTATE BIOPSY. Journal of Urology, 2017, 197, .	0.4	0
111	MP21-09 PROLONGED LENGTH OF STAY NOT ASSOCIATED WITH DECREASED HOSPITAL READMISSIONS FOLLOWING UNCOMPLICATED HOSPITALIZATION AFTER RADICAL CYSTECTOMY. Journal of Urology, 2017, 197, .	0.4	0
112	MP16-09 REEXAMINING THE ROLE OF EXTENDED LYMPHADENECTOMY FOR THE MANAGEMENT OF RENAL MALIGNANCY IN THE TARGETED THERAPY ERA. Journal of Urology, 2017, 197, .	0.4	0
113	Early Adoption of MRI-Guided Prostate Biopsies Rose Rapidly among Men with Private Health Insurance. Journal of the American College of Surgeons, 2017, 225, S114-S115.	0.5	Ο
114	Trends and Characteristics of Prophylactic Antibiotics for Men Undergoing Prostate Biopsy. Journal of the American College of Surgeons, 2018, 227, S284.	0.5	0
115	Surgical Sterilization among Men and Women in the US with Employer-Based Insurance. Journal of the American College of Surgeons, 2018, 227, S284.	0.5	Ο
116	High Preoperative Neutrophil-to-Lymphocyte Ratio Predicts Overall Survival in Localized and Metastatic Clear Cell Renal Cell Carcinoma. Journal of the American College of Surgeons, 2018, 227, e243.	0.5	0
117	Serial Measurements of C-Reactive Protein: Albumin Ratio Can Stratify Risk and Survival in Patients with Clear Cell Renal Cell Carcinoma. Journal of the American College of Surgeons, 2018, 227, e245.	0.5	Ο
118	New Preoperative Inflammatory Score Is an Independent and Significant Predictor of Overall Survival in Localized Clear Cell Renal Cell Carcinoma. Journal of the American College of Surgeons, 2018, 227, e244.	0.5	0
119	Selective modification of fluciclovine (18F) transport in prostate carcinoma xenografts. Amino Acids, 2018, 50, 1301-1305.	2.7	Ο
120	Proposal for tripartite reclassification of cT1 renal cell carcinoma into cT1a (very low risk), cT1b (low risk), and cT1c (intermediate risk) substages. European Urology Supplements, 2019, 18, e152-e153.	0.1	0
121	Elevated C-reactive protein is associated with functional decline following surgery for renal cell carcinoma: Results of an international cohort study. European Urology Supplements, 2019, 18, e1409-e1410.	0.1	Ο
122	Outcomes in Renal Cell Carcinoma Patients Undergoing IVC Ligation vs Thrombectomy: A Retrospective, Case-Controlled Study. Journal of the American College of Surgeons, 2019, 229, S318-S319.	0.5	0
123	Variation in Estimated Glomerular Filtration Rate Values Before Nephrectomy Based on Cystatin C, Chronic Kidney Disease Epidemiology Collaboration, Cockcroft-Gault, and Modification of Diet in Renal Disease Formulas. Journal of the American College of Surgeons, 2019, 229, S323.	0.5	Ο
124	A Helpful Tool in the Renal Surgery Armamentarium: Dorsal Lumbotomy nephrectomy for Tumor in Patients with End-Stage Renal Disease. Urology, 2021, 153, 327-332.	1.0	0
125	Influence of Paternal Race on Characteristics and Outcomes of Assisted Reproductive Technologies. Urology, 2021, , .	1.0	0
126	Cancer-specific outcomes for prostate cancer patients who had prebiopsy prostate MRI. Urologic Oncology: Seminars and Original Investigations, 2021, 40, 58.e9-58.e9.	1.6	0

#	Article	IF	CITATIONS
127	Evaluation of major histocompatibility complex class I expression in clear cell renal cell carcinoma as a prognostic tool Journal of Clinical Oncology, 2015, 33, 469-469.	1.6	0
128	Characterization and survival of patients presenting with PSA values 100 or greater Journal of Clinical Oncology, 2015, 33, e16127-e16127.	1.6	0
129	A novel preoperative inflammatory marker prognostic score in patients with clear cell renal cell carcinoma Journal of Clinical Oncology, 2016, 34, 566-566.	1.6	0
130	A novel preoperative inflammatory marker prognostic score in patients with clear cell and non-clear cell carcinoma Journal of Clinical Oncology, 2016, 34, 530-530.	1.6	0
131	The relationship between preoperative c-reactive protein and Fuhrman nuclear grade in stage T1 renal cell carcinoma Journal of Clinical Oncology, 2016, 34, 593-593.	1.6	0
132	Abstract 4241: Circulating microRNAs in plasma of men screened for prostate cancer. , 2017, , .		0
133	Impact of diabetes mellitus on functional and survival outcomes in renal cell carcinoma: An international multicenter study Journal of Clinical Oncology, 2020, 38, 666-666.	1.6	0
134	A randomized, controlled trial for transurethral treatment of bladder tumors using PlasmaButton vaporization electrode or monopolar loop electrocautery. Canadian Journal of Urology, 2019, 26, 9908-9915.	0.0	0
135	Does presence of diabetes mellitus impact patient oncological outcomes in renal cell carcinoma: A multicenter analysis Journal of Clinical Oncology, 2022, 40, 325-325.	1.6	0
136	Referral Patterns for Infertile Men: Predictors of Continued Treatment by Reproductive Endocrinologist versus Referral to a Nearby Urologist. Urology Practice, 0, , .	0.5	0
137	Role of Progressive Urethral Dilation and Primary Valve Ablation in the Long-Term Renal Outcomes of Small, Preterm Infants with Posterior Urethral Valve. Journal of Pediatric Urology, 2022, , .	1.1	0